GlassScriptPhysician profile
Minna Shaba
NPI 1770308884
$1,656.98
in general payments reported to CMS, 2019-2025
21 companies · $1,657 in 2025
The $1,657 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,558 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,557.98 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $328.59 | 2025 | |
| Janssen Biotech, INC. | $281.55 | 2025 | Tremfya, Stelara, Simponi Aria |
| Incyte Corporation | $246.55 | 2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $166.83 | 2025 | Dupixent |
| Abbvie INC. | $111.26 | 2025 | |
| Novartis Pharmaceuticals Corporation | $74.49 | 2025 | |
| Ucb, INC. | $72.01 | 2025 | Bimzelx |
| Lnhc, INC | $69.02 | 2025 | Zelsuvmi |
| Lilly USA, LLC | $55.76 | 2025 | Taltz, Ebglyss |
| Kerecis Limited | $43.93 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Arcutis Biotherapeutics, INC. | $32.80 | 2025 | Zoryve |
| Cipher Pharmaceuticals US LLC | $21.87 | 2025 | Spinosad, Natroba |
| Pfizer INC. | $21.84 | 2025 | |
| Botanix Sb INC | $19.75 | 2025 | Sofdra |
| Krystal Biotech INC | $17.42 | 2025 | Vyjuvek |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medline Industries LP | $16.76 | 2025 | |
| Organon LLC | $16.72 | 2025 | Hadlima |
| Verrica Pharmaceuticals INC. | $15.44 | 2025 | Ycanth |
| E.R. Squibb & Sons, L.L.C. | $15.18 | 2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $14.73 | 2025 | |
| Galderma Laboratories, L.P. | $14.48 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minna Shaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.